Actively Recruiting
The Role of IL5 in Epithelial Cell Integrity
Led by Johns Hopkins University · Updated on 2026-01-12
8
Participants Needed
2
Research Sites
21 weeks
Total Duration
On this page
Sponsors
J
Johns Hopkins University
Lead Sponsor
G
GlaxoSmithKline
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying chronic rhinosinusitis with nasal polyps to understand how the drug mepolizumab affects the health and function of nasal airway cells. This early-phase laboratory study focuses on how mepolizumab may reduce inflammation and help maintain the barrier integrity of epithelial cells lining the nasal passages. The goal is to see how anti-IL5 treatment might improve cell function by reducing inflammation and epithelial dysfunction in nasal tissues. The study involves exposing human nasal epithelial cells, collected from patients with chronic rhinosinusitis with nasal polyps, to mepolizumab in a laboratory setting. These cells will be compared to cells exposed only to culture media without the drug. Researchers will examine the impact of mepolizumab on various inflammatory markers and epithelial barrier proteins over a period of up to 48 hours using advanced RNA sequencing and protein analysis techniques. This approach helps identify how anti-IL5 therapy influences immune responses and cell integrity. Participants provide nasal epithelial cells for laboratory testing. Researchers will measure changes in Type 1, Type 2, and innate immune inflammatory markers, as well as proteins related to epithelial barrier function and cell integrity during the 48-hour study period. The study is non-randomized with no masking, and results will help identify potential biomarkers related to anti-IL5 treatment effects. The trial is sponsored by Johns Hopkins University and includes adults aged 18 to 100 years with confirmed chronic rhinosinusitis with nasal polyps.
CONDITIONS
Brief Title
The Role of IL5 in Epithelial Cell Integrity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 100 years
- Sinonasal inflammation lasting more than 12 weeks with at least two symptoms such as nasal obstruction, nasal discharge, facial pressure or pain, or reduced sense of smell
- Confirmation of symptoms by CT scan evidence of sinus inflammation or endoscopic exam showing purulence
- Presence of nasal polyps confirmed by endoscopic exam or sinus CT scan
You will not qualify if you...
- Children under 18 years old
- Pregnant or lactating females
- Prisoners
- Mentally disabled individuals
- Persons unable to give informed consent
- Disease caused by clear anatomical issues like facial trauma or sinonasal tumors
- Use of oral or intravenous glucocorticoids within 2 weeks before surgery
- Use of immunomodulatory biologic drugs such as omalizumab, dupilumab, mepolizumab, benralizumab, reslizumab, or rituximab
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Trial Site Locations
Total: 2 locations
1
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States, 21117
Actively Recruiting
2
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287
Actively Recruiting
Research Team
J
Jean Kim, MD PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here